Guided Therapeutics (GTHP) Total Debt Growth (5y) (2015 - 2025)
Guided Therapeutics (GTHP) Total Debt Growth (5y) (2015 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - |
| 10 | Guided Therapeutics | 21.96 Mn | 21.89 Mn | 458,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -42.05% |
| Sep 30, 2025 | -10.32% |
| Jun 30, 2025 | -43.05% |
| Mar 31, 2025 | -41.07% |
| Dec 31, 2024 | -39.27% |
| Sep 30, 2024 | 12.45% |
| Jun 30, 2024 | 16.59% |
| Mar 31, 2024 | -49.80% |
| Sep 30, 2023 | -43.51% |
| Jun 30, 2023 | -10.36% |
| Mar 31, 2023 | -52.12% |
| Dec 31, 2022 | -41.69% |
| Sep 30, 2022 | -6.28% |
| Jun 30, 2022 | -33.43% |
| Mar 31, 2022 | -46.13% |
| Dec 31, 2021 | -19.54% |
| Sep 30, 2021 | 9.26% |
| Jun 30, 2021 | 8.06% |
| Mar 31, 2021 | 0.90% |
| Dec 31, 2020 | 21.49% |